| Not Yet Recruiting | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas NCT07468136 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma NCT07480941 | Beijing Biotech | Phase 1 |
| Recruiting | T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant NCT07447531 | John M. Buatti | N/A |
| Withdrawn | Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma NCT05773664 | City of Hope Medical Center | Phase 1 |
| Recruiting | Fitness and Nutrition in Glioma NCT06665373 | NYU Langone Health | N/A |
| Recruiting | Mapping of Electrical Properties in the Brain NCT06470711 | Mayo Clinic | — |
| Recruiting | Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Gliom NCT05717153 | Mayo Clinic | EARLY_Phase 1 |
| Recruiting | Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial NCT05030298 | Mayo Clinic | Phase 1 |
| Recruiting | CARv3-TEAM-E T Cells in Glioblastoma NCT05660369 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Recruiting | Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant NCT05293197 | Assistance Publique - Hôpitaux de Paris | Phase 1 |
| Recruiting | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontin NCT05099003 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune NCT04817254 | National Cancer Institute (NCI) | Phase 2 |
| Completed | The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation NCT04937413 | Duke University | EARLY_Phase 1 |
| Active Not Recruiting | Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma NCT05045027 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Unknown | Personalized Vaccine for Patients With Recurrent Malignant Glioma NCT04943718 | Xuanwu Hospital, Beijing | Phase 1 |
| Withdrawn | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer NCT04521946 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy NCT04650204 | Mayo Clinic | Phase 4 |
| Recruiting | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children NCT04323046 | Sabine Mueller, MD, PhD | Phase 1 |
| Active Not Recruiting | D2C7-IT With Atezolizumab for Recurrent Gliomas NCT04160494 | Darell Bigner | Phase 1 |
| Active Not Recruiting | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Gra NCT03919071 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma NCT03973879 | Darell Bigner | Phase 1 / Phase 2 |
| Unknown | Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas NCT04197492 | Huashan Hospital | Phase 2 |
| Active Not Recruiting | Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas. NCT04175301 | Stony Brook University | Phase 2 |
| Suspended | Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR NCT03952598 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Psychological Intervention For Brain Tumor Caregivers NCT04109209 | Massachusetts General Hospital | N/A |
| Completed | Treatment Decision-making in Patients With Recurrent High-grade Glioma NCT04013828 | Odense University Hospital | — |
| Completed | Mindfulness Meditation in Glioma Patients NCT03915912 | Duke University | N/A |
| Active Not Recruiting | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas NCT03749187 | University of California, San Francisco | Phase 1 |
| Recruiting | Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Gr NCT04771806 | M.D. Anderson Cancer Center | — |
| Completed | 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblasto NCT03778294 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype NCT03718767 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Psychological Intervention for Caregivers of Patients With Malignant Gliomas NCT03735498 | Massachusetts General Hospital | N/A |
| Recruiting | Non-invasive Glioma Characterization Through Molecular Imaging NCT03684109 | University of Miami | N/A |
| Active Not Recruiting | 9-ING-41 in Patients With Advanced Cancers NCT03678883 | Actuate Therapeutics Inc. | Phase 2 |
| Withdrawn | Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas NCT03956706 | Northwell Health | N/A |
| Completed | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patient NCT03746080 | Lawrence D Recht | Phase 2 |
| Active Not Recruiting | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma With NCT03581292 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas NCT02659800 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma NCT03893903 | German Cancer Research Center | Phase 1 |
| Completed | Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Gli NCT03615404 | Gary Archer Ph.D. | Phase 1 |
| Active Not Recruiting | Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma NCT03389230 | City of Hope Medical Center | Phase 1 |
| Completed | Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields NCT03501134 | Duke University | — |
| Active Not Recruiting | PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma NCT03299309 | Daniel Landi | Phase 1 |
| Completed | Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Care NCT04630379 | Mayo Clinic | N/A |
| Recruiting | Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery NCT03510208 | Stanford University | Phase 1 / Phase 2 |
| Terminated | Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas NCT03334305 | University of Florida | Phase 1 |
| Completed | Early Palliative Care Intervention in Malignant Glioma NCT03471546 | Duke University | N/A |
| Unknown | Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent Hig NCT03411408 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | N/A |
| Completed | Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors NCT03387020 | Pediatric Brain Tumor Consortium | Phase 1 |
| Completed | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children NCT03043391 | Istari Oncology, Inc. | Phase 1 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Mind-Body Intervention in Glioma Couples NCT03244995 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lerapolturev in Recurrent Malignant Glioma NCT02986178 | Istari Oncology, Inc. | Phase 2 |
| Active Not Recruiting | Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With NCT03033992 | Children's Oncology Group | N/A |
| Terminated | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) NCT02924038 | Nicholas Butowski | Phase 1 |
| Terminated | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma NCT02663271 | University of Florida | Phase 2 |
| Completed | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma NCT02794883 | Northwestern University | Phase 2 |
| Completed | Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma NCT02549833 | Jennie Taylor | Phase 1 |
| Terminated | Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery NCT02855086 | Eben Rosenthal | Phase 1 / Phase 2 |
| Terminated | First in Patient Study for PF-06840003 in Malignant Gliomas NCT02764151 | Pfizer | Phase 1 |
| Completed | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurren NCT02829931 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer NCT02903069 | Celgene | Phase 1 |
| Completed | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme NCT02465268 | University of Florida | Phase 2 |
| Completed | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma NCT02661282 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain NCT02457845 | Gregory K. Friedman, MD | Phase 1 |
| Completed | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors NCT02644291 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma NCT02540161 | Annick Desjardins | Phase 2 |
| Completed | Nivolumab With DC Vaccines for Recurrent Brain Tumors NCT02529072 | Gary Archer Ph.D. | Phase 1 |
| Completed | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas NCT02323880 | Children's Oncology Group | Phase 1 |
| Completed | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers NCT02526017 | Five Prime Therapeutics, Inc. | Phase 1 |
| Completed | Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma NCT02507583 | david andrews | Phase 1 |
| Completed | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma NCT02590263 | AbbVie | Phase 1 / Phase 2 |
| Completed | MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas NCT02311582 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade NCT02313272 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diff NCT02359565 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Radionecrosis and FDG PET NCT02391246 | Ottawa Hospital Research Institute | — |
| Completed | D2C7 for Adult Patients With Recurrent Malignant Glioma NCT02303678 | Darell Bigner | Phase 1 |
| Completed | Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib NCT02330562 | Celgene | Phase 1 / Phase 2 |
| Terminated | FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas NCT02371031 | Washington University School of Medicine | Phase 1 |
| Completed | Molecular Characterization of Gliomas Using a Broad Next Generation Sequencing (NGS)Panel NCT05486247 | Hellenic Cooperative Oncology Group | — |
| Terminated | Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Re NCT02375334 | Wake Forest University Health Sciences | — |
| Completed | Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma NCT02278510 | Michael Vogelbaum, MD, PhD | EARLY_Phase 1 |
| Completed | Early-Phase Safety of Proton Therapy Equipment NCT02315989 | Chang Gung Memorial Hospital | N/A |
| Active Not Recruiting | A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas NCT02104310 | Mayo Clinic | — |
| Completed | Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma NCT01811992 | University of Michigan Rogel Cancer Center | Phase 1 |
| Completed | Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas NCT02186262 | Turku University Hospital | — |
| Unknown | Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics NCT02047058 | Nanfang Hospital, Southern Medical University | — |
| Completed | 18F-DOPA-PET in Planning Surgery in Patients With Gliomas NCT02020720 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Pati NCT02300506 | Eisai Co., Ltd. | — |
| Completed | 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy NCT01991977 | Mayo Clinic | Phase 2 |
| Terminated | Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma NCT02039778 | Beth Israel Medical Center | N/A |
| Completed | Prognostic Awareness and Patient-Physician Communication in Malignant Glioma NCT02023346 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma NCT01808820 | Macarena De La Fuente, MD | Phase 1 |
| Completed | A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High NCT01891747 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Terminated | FMISO-PET in Brain Tumors and SCS Effect NCT01868906 | Bernardino Clavo, MD, PhD | Phase 2 |
| Completed | Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma NCT01817751 | Virginia Commonwealth University | Phase 2 |
| Completed | Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study) NCT02300532 | Eisai Co., Ltd. | — |
| Completed | Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients NCT01738646 | Duke University | Phase 2 |
| Completed | Bevacizumab Beyond Progression (BBP) NCT01740258 | Duke University | Phase 2 |
| Terminated | Lacosamide in Preventing Seizures in Participants With Malignant Glioma NCT01432171 | M.D. Anderson Cancer Center | N/A |
| Completed | CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII NCT01454596 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | PVSRIPO for Recurrent Glioblastoma (GBM) NCT01491893 | Istari Oncology, Inc. | Phase 1 |
| Terminated | Image Guided Reirradiation of High-grade Glioma NCT02025231 | Rigshospitalet, Denmark | Phase 1 / Phase 2 |
| Terminated | MRI-Guided Laser Induced Thermal Therapy NCT01515085 | Rutgers, The State University of New Jersey | — |
| Completed | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurren NCT01266031 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma NCT01392209 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastase NCT01386580 | BBB-Therapeutics B.V. | Phase 1 / Phase 2 |
| Terminated | A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors NCT01351519 | MultiCare Health System Research Institute | Phase 2 |
| Completed | Low Dose Naltrexone for Glioma Patients NCT01303835 | Katy Peters | Phase 2 |
| Completed | AZD8055 for Adults With Recurrent Gliomas NCT01316809 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma NCT01235845 | Qingdao University | Phase 1 / Phase 2 |
| Terminated | Nuvigil or Placebo in Newly Diagnosed Malignant Glioma NCT01400958 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors NCT00634231 | Candel Therapeutics, Inc. | Phase 1 |
| Completed | Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma NCT02861222 | Central Hospital, Nancy, France | Phase 1 |
| Completed | Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas NCT01167322 | Nobelpharma | Phase 3 |
| Completed | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma NCT01004874 | Duke University | Phase 2 |
| Completed | Radiosurgery and Avastin for Recurrent Malignant Gliomas NCT01017250 | Duke University | N/A |
| Completed | Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma NCT01792505 | Cedars-Sinai Medical Center | Phase 1 |
| Completed | Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG) NCT00953121 | Annick Desjardins | Phase 2 |
| Completed | Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide NCT00900757 | Duke University | Phase 2 |
| Completed | Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme NCT00919737 | Nobelpharma | Phase 1 / Phase 2 |
| Completed | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma NCT00859222 | Patrick Y. Wen, MD | Phase 1 / Phase 2 |
| Terminated | A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) NCT00735436 | Duke University | Phase 2 |
| Completed | Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma NCT00782756 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas NCT00766467 | Eudocia Quant Lee, MD | Phase 2 |
| Unknown | A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma NCT00683761 | TransMolecular | Phase 1 / Phase 2 |
| Completed | Study of Capecitabine to Treat Recurrent High Grade Gliomas NCT00717197 | University of Florida | Phase 2 |
| Completed | Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over NCT02892708 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Unknown | Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma NCT00591058 | TransMolecular | Phase 1 |
| Completed | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme NCT00458601 | Celldex Therapeutics | Phase 2 |
| Completed | Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients NCT00576446 | Cedars-Sinai Medical Center | Phase 1 |
| Completed | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma NCT00589875 | Candel Therapeutics, Inc. | Phase 2 |
| Completed | Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas NCT00766753 | Frank Lieberman | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas NCT00528684 | Oncolytics Biotech | Phase 1 |
| Completed | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas NCT00751270 | Candel Therapeutics, Inc. | Phase 1 |
| Completed | G207 Followed by Radiation Therapy in Malignant Glioma NCT00157703 | MediGene | Phase 1 |
| Completed | Characterization of Serial Magnetic Resonance Spectroscopy Imaging in Patients With Malignant Glioma Undergoin NCT00125697 | AHS Cancer Control Alberta | — |
| Unknown | 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma NCT00114309 | TransMolecular | Phase 2 |
| Completed | Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) NCT00087451 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases NCT00103038 | OHSU Knight Cancer Institute | N/A |
| Completed | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recu NCT00064779 | INSYS Therapeutics Inc | Phase 1 |
| Unknown | Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Pa NCT00075387 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | A Study of LY317615 in Patients With Brain Tumors NCT00190723 | Eli Lilly and Company | Phase 2 |
| Completed | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma NCT00041587 | INSYS Therapeutics Inc | Phase 1 / Phase 2 |
| Completed | This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma. NCT00032903 | Sigma-Tau Research, Inc. | Phase 1 / Phase 2 |
| Completed | High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma NCT00283556 | Kentuckiana Cancer Institute | Phase 1 / Phase 2 |
| Completed | Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant G NCT00024557 | INSYS Therapeutics Inc | Phase 1 |
| Completed | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma NCT00024570 | INSYS Therapeutics Inc | Phase 1 / Phase 2 |
| Completed | Comparative 2-D Tumor Analysis in Familial Gliomas NCT00125710 | AHS Cancer Control Alberta | — |
| Withdrawn | Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients NCT01952886 | Duke University | Phase 2 |
| Withdrawn | MK-2206 for Recurrent Malignant Glioma NCT01249105 | Dana-Farber Cancer Institute | Phase 2 |